Literature DB >> 24612612

Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients.

Melanie Gaubert1, Marc Laine1, Toesca Richard2, Nathalie Fournier2, Christophe Gramond3, Jacques Bessereau2, Zaïr Mokrani4, Bruno Bultez5, Virginie Chelini6, Pierre Barnay7, Luc Maillard8, Franck Paganelli1, Laurent Bonello9.   

Abstract

Entities:  

Keywords:  Acute coronary syndrome; Compliance; Dyspnea; Side effects; Ticagrelor

Mesh：

Substances：

Year:  2014        PMID： 24612612     DOI： 10.1016/j.ijcard.2014.02.028

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  5 in total

Review 1.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Authors:  Fabiana Rollini; Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2015-08-18       Impact factor: 32.419

2.  Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Authors:  Ricky D Turgeon; Sheri L Koshman; Erik Youngson; Bryan Har; Stephen B Wilton; Matthew T James; Michelle M Graham
Journal:  JAMA Intern Med       Date:  2020-03-01       Impact factor: 21.873

3.  Real-world incidence of patient-reported dyspnoea with ticagrelor.

Authors:  Adaire E Prosser; Jessica L Dawson; KethLyn Koo; Karen M O'Kane; Michael B Ward; Richard J Woodman; Arduino A Mangoni; Cameron J Phillips
Journal:  Ther Adv Drug Saf       Date:  2018-08-09

4.  Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention.

Authors:  Sri Raveen Kandan; Thomas W Johnson
Journal:  Interv Cardiol       Date:  2015-03

Review 5.  Novel antiplatelet agents in acute coronary syndrome.

Authors:  Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2014-10-07       Impact factor: 32.419
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.